Want to see TECX full AI Analyst Report?
TECX Stock Chart & Stats
$37.71
-$1.24(-3.92%)
At close: 4:00 PM EDT
$37.71
-$1.24(-3.92%)
Day’s Range― - ―
52-Week Range$15.32 - $39.53
Previous Close$30.37
Volume99.11K
Average Volume (3M)245.96K
Market Cap
$444.75M
Enterprise Value$429.22M
Total Cash (Recent Filing)$227.07M
Total Debt (Recent Filing)$4.40M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Nov 05, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.57
Shares Outstanding19,549,366
10 Day Avg. Volume325,933
30 Day Avg. Volume245,961
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.12
Forecast
1Y Price Target
$78.67Price Target Upside108.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage gives Tectonic greater financial flexibility while it funds its development programs. The substantial equity and asset base can support continued research and clinical work, and reduces near-term balance-sheet pressure relative to a highly indebted biotechnology company.
Positive TX2100 Clinical And Regulatory ProgressTX2100 has moved beyond initial preparation with favorable first-in-human safety, tolerability and target-engagement results, FDA IND clearance, and Fast Track status. These milestones support advancement into patient studies and create a clearer development path in a rare disease with high unmet need.
Focused GPCR Discovery PlatformA focused GPCR research strategy provides a consistent scientific foundation for advancing multiple therapeutic candidates through discovery, preclinical work and clinical development. This platform orientation may support continued pipeline creation beyond any single program, including potential partner-led development.
Bears Say
No Commercial Revenue And Widening LossesTectonic remains pre-revenue while losses are expanding as it invests ahead of commercialization. Without product revenue, the company has limited internally generated funding for research and trials, making future progress dependent on maintaining access to external capital or partnerships.
Accelerating Cash BurnThe rising cash outflow increases the funding required to sustain operations and advance clinical programs. Although the balance sheet is lightly levered, continued negative operating and free cash flow can reduce financial flexibility over time and make funding durability a central execution issue.
TX2100 Remains Early-stageTX2100 has encouraging early data, but its evidence currently comes from a small Phase 1a study in healthy volunteers. Patient efficacy and later-stage confirmation remain ahead, so the pipeline’s commercial potential still depends on successful execution through multiple upcoming development stages.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $15.31 and its highest was $39.53 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Tectonic Therapeutic’s market cap is $444.75M.
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is Nov 05, 2026 which is in 26 days.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Aug 06, 2026. The company reported -$1.18 earnings per share for the quarter, beating the consensus estimate of -$1.349 by $0.169.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -1.33.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 19,549,366 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$1.18 in its last earnings report, beating expectations of -$1.349. Following the earnings report the stock price went up 2.515%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.67 (108.61% Upside)
$78.67 (108.61% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 19.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
48.11%
12-Months-Change
Fundamentals
Return on Equity
-35.26%
Trailing 12-Months
Asset Growth
-19.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tectonic Therapeutic
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$78.67
▲(108.61% Upside)
Technical Analysis
Ownership Overview
34.38% Insiders
14.50% Mutual Funds
29.81% Other Institutional Investors
14.68% Public Companies and
Individual Investors